Glasgow-based life sciences company EnteroBiotix has secured £19 million in funding to support the advancement of its microbiome-based therapies, including a large-scale clinical trial targeting irritable bowel syndrome (IBS). The round was led by Thairm Bio and the Scottish National Investment Bank, with participation from existing investors. The company has raised more than £65 million to date.
Founded in 2017 by Dr James McIlroy, EnteroBiotix develops microbiome-based therapeutics designed to address underlying disease biology.
The newly raised capital will primarily support a Phase 2b clinical trial of EBX-102-02, the company’s lead candidate for IBS. The study, involving approximately 300 patients, is already underway, with topline efficacy data expected in the second half of 2027.
IBS affects a significant proportion of the global population and represents a substantial unmet medical need. EnteroBiotix’s approach differs from conventional probiotics by aiming to restore the microbiome more comprehensively, with the goal of improving patient outcomes at scale.
Our clinical data indicates that EBX-102-02 has the potential to deliver meaningful outcomes for patients with IBS. Our goal is to address the underlying causes of disease and improve standards of care in gastrointestinal health,
said Dr James McIlroy, founder of EnteroBiotix.
The company has established a number of strategic partnerships and research collaborations, including with Imperial College London, as it continues to advance its development programmes and expand its presence in the global biopharmaceutical sector.
The funding will also be used to advance EnteroBiotix’s broader clinical pipeline, scale manufacturing capabilities, and support ongoing research and development efforts.
Would you like to write the first comment?
Login to post comments